These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ. O'Nuallain B; Klyubin I; Mc Donald JM; Foster JS; Welzel A; Barry A; Dykoski RK; Cleary JP; Gebbink MF; Rowan MJ; Walsh DM J Neurochem; 2011 Oct; 119(1):189-201. PubMed ID: 21781116 [TBL] [Abstract][Full Text] [Related]
4. Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity. Welzel AT; Maggio JE; Shankar GM; Walker DE; Ostaszewski BL; Li S; Klyubin I; Rowan MJ; Seubert P; Walsh DM; Selkoe DJ Biochemistry; 2014 Jun; 53(24):3908-21. PubMed ID: 24840308 [TBL] [Abstract][Full Text] [Related]
5. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Shankar GM; Li S; Mehta TH; Garcia-Munoz A; Shepardson NE; Smith I; Brett FM; Farrell MA; Rowan MJ; Lemere CA; Regan CM; Walsh DM; Sabatini BL; Selkoe DJ Nat Med; 2008 Aug; 14(8):837-42. PubMed ID: 18568035 [TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. Barry AE; Klyubin I; Mc Donald JM; Mably AJ; Farrell MA; Scott M; Walsh DM; Rowan MJ J Neurosci; 2011 May; 31(20):7259-63. PubMed ID: 21593310 [TBL] [Abstract][Full Text] [Related]
7. Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies. Rowan MJ; Klyubin I; Wang Q; Anwyl R Biochem Soc Trans; 2005 Aug; 33(Pt 4):563-7. PubMed ID: 16042545 [TBL] [Abstract][Full Text] [Related]
8. Human Brain-Derived Aβ Oligomers Bind to Synapses and Disrupt Synaptic Activity in a Manner That Requires APP. Wang Z; Jackson RJ; Hong W; Taylor WM; Corbett GT; Moreno A; Liu W; Li S; Frosch MP; Slutsky I; Young-Pearse TL; Spires-Jones TL; Walsh DM J Neurosci; 2017 Dec; 37(49):11947-11966. PubMed ID: 29101243 [TBL] [Abstract][Full Text] [Related]
10. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. Lee EB; Leng LZ; Zhang B; Kwong L; Trojanowski JQ; Abel T; Lee VM J Biol Chem; 2006 Feb; 281(7):4292-9. PubMed ID: 16361260 [TBL] [Abstract][Full Text] [Related]
11. Peripherally administered sera antibodies recognizing amyloid-β oligomers mitigate Alzheimer's disease-like pathology and cognitive decline in aged 3× Tg-AD mice. Wang HC; Yu YZ; Liu S; Zhao M; Xu Q Vaccine; 2016 Apr; 34(15):1758-66. PubMed ID: 26945100 [TBL] [Abstract][Full Text] [Related]
12. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218 [TBL] [Abstract][Full Text] [Related]
13. A novel antibody targeting sequence 31-35 in amyloid β protein attenuates Alzheimer's disease-related neuronal damage. Cheng L; Zhang J; Li XY; Yuan L; Pan YF; Chen XR; Gao TM; Qiao JT; Qi JS Hippocampus; 2017 Feb; 27(2):122-133. PubMed ID: 27784133 [TBL] [Abstract][Full Text] [Related]
14. Preparation and in vitro activity of single chain antibodies against Alzheimer's disease. Fu L; Zhang Y; Zhang X; Tian W; Zhang W; Jia Y; Zhang L Immunol Lett; 2020 Nov; 227():1-7. PubMed ID: 32781005 [TBL] [Abstract][Full Text] [Related]
15. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease. Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172 [TBL] [Abstract][Full Text] [Related]
16. Improved Brain Expression of Anti-Amyloid β scFv by Complexation of mRNA Including a Secretion Sequence with PEG-based Block Catiomer. Perche F; Uchida S; Akiba H; Lin CY; Ikegami M; Dirisala A; Nakashima T; Itaka K; Tsumoto K; Kataoka K Curr Alzheimer Res; 2017; 14(3):295-302. PubMed ID: 27829339 [TBL] [Abstract][Full Text] [Related]
17. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Selkoe DJ Behav Brain Res; 2008 Sep; 192(1):106-13. PubMed ID: 18359102 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Herline K; Prelli F; Mehta P; MacMurray C; Goñi F; Wisniewski T Alzheimers Res Ther; 2018 Jun; 10(1):54. PubMed ID: 29914551 [TBL] [Abstract][Full Text] [Related]
19. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Holtzman DM; Bales KR; Paul SM; DeMattos RB Adv Drug Deliv Rev; 2002 Dec; 54(12):1603-13. PubMed ID: 12453677 [TBL] [Abstract][Full Text] [Related]
20. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer's brain. Li S; Selkoe DJ J Neurochem; 2020 Sep; 154(6):583-597. PubMed ID: 32180217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]